ArticleInternational journal of chronic obstructive pulmonary disease2026
Effective-Component Compatibility of Bufei Yishen Formula Alleviates Alveolar Epithelial Barrier Damage in COPD Through Inhibition of p38 MAPK Phosphorylation.
Article in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Alveolar epithelial barrier (AEB) dysfunction drives the development of chronic obstructive pulmonary disease (COPD). This study aimed to investigate whether the effective-component compatibility of the Bufei Yishen formula (ECC-BYF) protects the AEB in COPD via anti-inflammatory mechanisms, and to elucidate the underlying pathways. Methods: In vivo, a rat model of COPD was established via repeated bacterial infection and cigarette smoke exposure. Following treatment, we analyzed lung function, histopathology, epithelial ultrastructure, inflammatory factors, and AEB-related protein expression. In vitro, MLE-12 cells stimulated with TNF-α were pretreated with ECC-BYF to assess cell viability, inflammatory responses, and barrier protein expression. Additionally, network pharmacology was utilized to predict key therapeutic targets, and the involvement of the p38 MAPK signaling pathway was validated via Western blotting. Results: In vivo, ECC-BYF improved pulmonary function and attenuated histopathological damage in COPD rats. Ultrastructural analysis showed that ECC-BYF improved the morphology of alveolar type 1 (AT1) and type 2 (AT2) cells and preserved intercellular junctions. Furthermore, ECC-BYF upregulated the expression of ZO-1, Occludin, SP-C, and SP-D proteins, increased Interleukin (IL)-10 in bronchoalveolar lavage fluid (BALF), and suppressed BALF levels of IL-6, IL-1β, and TNF-α. Network pharmacology identified TNF/IL-6 and MAPK signaling as key targets. In vitro, ECC-BYF reversed TNF-α-induced elevations in IL-6 and TNF-α mRNA, increased ZO-1, Occludin, and SP-C protein levels, and inhibited p38 MAPK phosphorylation. This reduction in p-p38 MAPK was concordantly observed in rat lung tissues. Critically, asiatic acid abrogated ECC-BYF's suppressive effects, demonstrating that p38 MAPK inhibition is central to its barrier-protective efficacy. Conclusion: ECC-BYF mitigates AEB disruption in COPD by inhibiting the p38 MAPK-mediated inflammatory response, highlighting a crucial mechanism for protecting barrier integrity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.